PURPOSE: Transforming growth factor-beta1 (TGF-beta1) plays an important role in inflammation and immune responses, which control the human papillomavirus (HPV) clearance and escape of immune surveillance, and may contribute to genetic susceptibility to HPV16 infection. EXPERIMENTAL DESIGN: In this case series study, we analyzed the HPV16 status in tumor specimens and genotyped three TGF-beta1 polymorphisms using genomic DNA from the blood of 200 squamous cell carcinoma of the oropharynx (SCCOP) cases. We calculated odds ratio (OR) and 95% confidence intervals (95% CI) in univariate and multivariable logistic regression models to examine the association between the TGF-beta1 polymorphisms and HPV16 status in SCCOP. RESULTS: Compared with those with the common homozygous genotype, the TGF-beta1 T869C variant genotypes were significantly associated with HPV16-positive tumor status among patients with SCCOP (OR, 1.97; 95% CI, 1.03-3.76), but no significant association was observed for the TGF-beta1 C509T or G915C polymorphism. When all variant genotypes were combined, however, SCCOP patients carrying genotypes with any of these TGF-beta1 variants were more than twice as likely to have an HPV16-positive tumor (OR, 2.28; 95% CI, 1.16-4.50) as patients with no variant genotypes. The stratified analysis showed that those under 54 years of age, non-Hispanic white patients, never smokers, and never drinkers with any variant TGF-beta1 genotypes were also more likely to have HPV16-positive tumors. CONCLUSIONS: TGF-beta1 polymorphisms may serve as a susceptibility marker for tumor HPV16 status among SCCOP patients, particularly those who were never smokers and never drinkers. Large studies are needed to validate our findings.
PURPOSE:Transforming growth factor-beta1 (TGF-beta1) plays an important role in inflammation and immune responses, which control the human papillomavirus (HPV) clearance and escape of immune surveillance, and may contribute to genetic susceptibility to HPV16 infection. EXPERIMENTAL DESIGN: In this case series study, we analyzed the HPV16 status in tumor specimens and genotyped three TGF-beta1 polymorphisms using genomic DNA from the blood of 200 squamous cell carcinoma of the oropharynx (SCCOP) cases. We calculated odds ratio (OR) and 95% confidence intervals (95% CI) in univariate and multivariable logistic regression models to examine the association between the TGF-beta1 polymorphisms and HPV16 status in SCCOP. RESULTS: Compared with those with the common homozygous genotype, the TGF-beta1T869C variant genotypes were significantly associated with HPV16-positive tumor status among patients with SCCOP (OR, 1.97; 95% CI, 1.03-3.76), but no significant association was observed for the TGF-beta1C509T or G915C polymorphism. When all variant genotypes were combined, however, SCCOP patients carrying genotypes with any of these TGF-beta1 variants were more than twice as likely to have an HPV16-positive tumor (OR, 2.28; 95% CI, 1.16-4.50) as patients with no variant genotypes. The stratified analysis showed that those under 54 years of age, non-Hispanic white patients, never smokers, and never drinkers with any variant TGF-beta1 genotypes were also more likely to have HPV16-positive tumors. CONCLUSIONS:TGF-beta1 polymorphisms may serve as a susceptibility marker for tumorHPV16 status among SCCOP patients, particularly those who were never smokers and never drinkers. Large studies are needed to validate our findings.
Authors: Virginia G Kaklamani; Lisa Baddi; Junjian Liu; Diana Rosman; Sharbani Phukan; Ciarán Bradley; Chris Hegarty; Bree McDaniel; Alfred Rademaker; Carole Oddoux; Harry Ostrer; Loren S Michel; Helen Huang; Yu Chen; Habibul Ahsan; Kenneth Offit; Boris Pasche Journal: Cancer Res Date: 2005-04-15 Impact factor: 12.701
Authors: M L Gillison; W M Koch; R B Capone; M Spafford; W H Westra; L Wu; M L Zahurak; R W Daniel; M Viglione; D E Symer; K V Shah; D Sidransky Journal: J Natl Cancer Inst Date: 2000-05-03 Impact factor: 13.506
Authors: D J Grainger; K Heathcote; M Chiano; H Snieder; P R Kemp; J C Metcalfe; N D Carter; T D Spector Journal: Hum Mol Genet Date: 1999-01 Impact factor: 6.150
Authors: Caiyun Zhang; Erich M Sturgis; Hongliang Zheng; Xicheng Song; Peng Wei; Lei Jin; Li Chao; Qingyi Wei; Guojun Li Journal: Int J Cancer Date: 2013-10-24 Impact factor: 7.396
Authors: Fenghua Zhang; Erich M Sturgis; Yan Sun; Yang Zhang; Qingyi Wei; Caiyun Zhang; Hongliang Zheng; Guojun Li Journal: Int J Cancer Date: 2015-07-27 Impact factor: 7.396
Authors: Morgan A Gingerich; Joshua D Smith; Nicole L Michmerhuizen; Megan Ludwig; Samantha Devenport; Chloe Matovina; Chad Brenner; Steven B Chinn Journal: Head Neck Date: 2018-02-10 Impact factor: 3.147
Authors: Ye Tao; Erich M Sturgis; Zhigang Huang; Ying Wang; Peng Wei; Jennifer Rui Wang; Qingyi Wei; Guojun Li Journal: Clin Cancer Res Date: 2018-02-20 Impact factor: 12.531
Authors: Chaya Levovitz; Dan Chen; Emma Ivansson; Ulf Gyllensten; John P Finnigan; Sara Alshawish; Weijia Zhang; Eric E Schadt; Marshal R Posner; Eric M Genden; Paolo Boffetta; Andrew G Sikora Journal: Cancer Res Date: 2014-10-01 Impact factor: 12.701
Authors: Ye Tao; Erich M Sturgis; Zhigang Huang; Yan Sun; Kristina R Dahlstrom; Qingyi Wei; Guojun Li Journal: Int J Cancer Date: 2018-05-02 Impact factor: 7.396
Authors: Xiaoxiang Guan; Erich M Sturgis; Xicheng Song; Zhensheng Liu; Adel K El-Naggar; Qingyi Wei; Guojun Li Journal: Cancer Lett Date: 2012-12-05 Impact factor: 8.679